SavedAdd your journal

Journals / European Journal of Therapeutics / 2009 / Cilt: 15 Sayı: 3

Appoaches to anti-HLA antibody profiles in patients waiting for renal re-transolantation

Renal re-transplantasyona hazırlanan hastaların anti-HLA antikor durumları ile ilgili yaklaşımlar

Gonca Emel Karahan
Fatma Sevcan Oğuz
Mahmut N. Çarin
Pages
36–41
Publication Date
2009-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Beyond all these, a newly developed computer algorithm, 'HLAMatchmaker' has changed the concept of transplantation possibility in highly sensitized patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This review focuses on the mechanisms of anti-HLA antibody, development in patients waiting for a renal re-transplantation.
📊
Key Findings & Data:Pre'r existence or post transplant de novo production of these antibodies', have been found to contribute to renal allograft failure in years.
💡
Conclusion & Impact:Beyond all these, a newly developed computer algorithm, 'HLAMatchmaker' has changed the concept of transplantation possibility in highly sensitized patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:HLA antijenleri · Nefrektomi · Böbrek nakli

Abstract

This review focuses on the mechanisms of anti-HLA antibody, development in patients waiting for a renal re-transplantation. Pre'r existence or post transplant de novo production of these antibodies', have been found to contribute to renal allograft failure in years. In addition to the detrimental effect of donor specific and. nolvdonor. specific artti-HLA antibodies on graft survival, many, researchers emphasized the effect of non-HLA antibodies (e.g.; anti-MICA antibodies); auto-antibodies (e.g.; anti-vimentin antibodies), allo-nephrectömy and combined liver-kidney transplantations on rejection processes. Beyond all these, a newly developed computer algorithm, 'HLAMatchmaker' has changed the concept of transplantation possibility in highly sensitized patients.

Özet

Bu derleme, renal re-transplantasyoha hazırlanan hastalarda anti-HLA antikor gelişim metonizmatarına^daklahmaktadır. Bu antikorların nakil öncesi dönemde var olması veya nakil spnrası de noyo üretj'mteri yıllar içerisinde graft yetmezliği ile sonlanır. Dönore özgü olan,ya da olmayan bu anti-HLA antikorların graft sağkalımı üzerine olan hasarlayıcı etkilerine ek olarak, pek çok çalışmada HLA dışı antikorlar (örn; anti-MICA antikorları), oto-antikorlar, allo-nefrektomi ve karaciğer ve böbreğin birlikte naklinin rejeksiyon süreçlerine etkilerini incelenmiştir.,Bunların yanı sıra, son yıllarda geliştirilen ve 'HLAMatchmaker' olarak adlandırılan bir bilgisayar algoritması, bekleme listelerinde uzun yıllar bekleyen ve nakil olma ihtimalleri çok düşük olan yüksek oranda sensitize bireyler için umut ışığı olma özelliğindedir.

🔖

Cite This Article

Karahan, G. E., Oğuz, F. S., Çarin, M. N. (2009). Appoaches to anti-HLA antibody profiles in patients waiting for renal re-transolantation. European Journal of Therapeutics, Cilt: 15 Sayı: 3, 36–41. https://ajindex.com/articles/977071

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (48)

  1. Morris PJ, Mickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantations. XXII. Specificity of cytotoxic antibodies developing after renal transplantation. Br Med J. 1969;l:758-759
  2. Jeannet M, Pinn VW, Flax MH, Russell PS. Humoral antibodies in renal alotransplantation in man. N Engl J Med. 1970;282:111-117
  3. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation. 2000;69:319-326
  4. Terasaki P. Humoral theory of transplantation. Am J Transplant. 2003;3:665-673
  5. Kaufman A, de Souza Pontes LF, Queiroz Marques MT. Analysis of AHG-PRA and ELISA-PRA in kidney transplant patients with acute rejection episodes. Transplant Immunol. 2003;ll:175-178
  6. Crespo M, Lozano M, Sole M. Diagnosis and treatment of acute humoral rejection after kidney transplantation: preliminary experience. Transplant Proc. 2003;35:1677-1678
  7. Fernandez-Fresnedo G, Pastor JM, Lopez-Hoyos M. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrol Dial Transplant 2003; 18:990-995
  8. Pelletier RP, Hennessy PK, Adams PW, VanBuskirk AM, Ferguson RM, Orosz CG. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant. 2002;2:134-141
  9. Panigrahi A, Deka R, Bhowmik D, Tiwari SC, Mehra NK. Immunological monitoring of posttransplant allograft sensitization following living related donor renal transplantation. Transplant Proc. 2004;36:1336-1339
  10. lO.Crespo M, Pascual M, Tolkoff-Rubin Nal. Acute humoral rejection in renal allograft recipients: I.Incidence, serology and clinical characteristics. Transplantation. 2001:71:652-658
  11. ll.Varnavidou-Nicolaidou A, Doxiadis II, Iniotaki-Theodoraki A, Patargias T, Stavropoulos-Giokas C, Kyriakides GK. HLA class I donor-specific triplet antibodies detected after renal transplantation. Transplant Proc. 2004;36:1732-1734
  12. Hourmant M, Cesbron-Gautier A, Terasaki P. Frequency and clinical implication of development of donor-specific and non-donor specific HLA antibodies after kidney transplantation. J Am Soc Nephrol. 2005; 16:2804-2812
  13. Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant. 2001; 16:897-904
  14. Class FHJ and van Roood JJ. The hyperimmunized patient: from sensitziation toward transplantation. Transplant International. 1988; 1:53-57
  15. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M.Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet. 1989; 1:10-12
  16. Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis. 1990;16:423-431
  17. Lorenz M, Regele H, Schillinger M. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation. 2005;79:696-701
  18. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS, Fotino M, Friedlander R. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation. 2005;79:742
  19. Akalin E, Sehgal V, Murphy B. Intravenous assessment for antibody-mediated rejection and desensitization protocols. Transplantation. 2004;78:181-185
  20. Glotz D, Antoine C, Duboust A: Antidonor antibodies and transplantation: how to deal with them before and after transplantation. Transplantation. 2005;79:30-32
  21. Olausson M, Mjornstedt L, Norden G. Auxiliary liver and combined kidney transplantation prevents hyperacute kidney rejection in highly sensitized patients. Transplant Proc. 2002;34:3106-3107
  22. Gutierrez A, Crespo M, Mila J, Torregrosa JV, Martorell J, Oppenheimer F. Outcome of simultaneous liver-kidney transplantation in highly sensitized, crossmatch-positive patients. Transplant Proc. 2003;35:1861-1862
  23. Bjorkman PJ, Saper MA, Samraoui B, Bennet WS, Strominger Jl and Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987;329:506-512
  24. Rodey GE, Revels K, Fuller TC. Epitope specificity of HLA class I alloantibodies: II. Stability of cross-reactive group antibody patterns over extended time periods. Transplantation. 1997; 63:885-893. 25.Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA.Epitope specificity of HLA class I alloantibodies. Lfrequency analysis of to private versus public specificities in potential transplant recipients. Human Immunol. 1994;39:272-280
  25. 1dica A, Sasaki N, Hardy S and Terasaki PI. Unexpected frequencies of HLA antibody specifities present in sera of multitransfused patients. In TERASAKI PI,eds. Clinical Transplants. California: Terasaki Foundation Laboratory. 2006:139-160
  26. Mao Q, Terasaki PI, Cai J, El -Awar N and Rebellato L. Analysis of HLA class I-specific antibodies in patients wiht failed allografs. Transplantation. 2007;83:54-61
  27. Cai J, Terasaki PI, Mao Q, Pham T. Development of non-donor specific HLA-Dr antibodies in allograft recipients is associated with shared epiotopes with mismatched donor DR antigens. Am J Transplant. 2006;6:2947-2954
  28. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Human Immunol. 2006;67:847-862
  29. 3O.Adeyi OA, Girnita AL, Howe J. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol. 2005; 14:53-62
  30. Harmer AW, Koffman CG, Heads AJ, Vaughan RW. Sensitization to HLA antigens occurs in 95% of primary renal transplant rejections. Transplant Proc. 1995;27:666-667
  31. Lee PC, Terasaki PI, Takemoto SK. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation. 2002;74:1192-1194
  32. EI-Awar N, Terasaki PI, Lazda V, Nikaein A, Manning C, Armold AN. Almost all patients who are waiting for a regraft of a kidney transplant have anti HLA antibodies. Transplant Proc. 2002;34:2531-2532
  33. Worthington JE, Martin S, Dyer PA, Jahson RWG. An association between posttransplant antibody production and renal transplant rejection. Transplant Proc. 2001;33:475-476
  34. Zou Y, Mirbaha F, Lazaro A, Zhang Y, Lavingia B, Stastny P. MICA is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies. Hum Immunol. 2002;63:30-39
  35. Hankey KG, Drachenberg CB, Papadimitriou JC. MIC expression in renal and pancreatic allografts. Transplantation. 2002;73:304-306
  36. Zwirner NW, Marcos CY, Mirbaha F, Zou Y, Stastny P. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol. 2000;61:917-924
  37. 0guz F, Karahan G, Ozdilli K, Carin M. MHC and MIC genes in Autoimmunity. Turk J Immunol. 2005; 10:1-7
  38. Smith JD, Rose M. Detection and clinical relevance of antibodies after. Transplantation. 2006;333:227-246
  39. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, and Rose ML. Autoantibodies to Vimentin Cause Accelerated Rejection of Cardiac Allografts. Am J Patho. 2007; 170:1415-1427
  40. Feucht HE. Complement C4d in graft capillaries—the missing link in the recognition of humoral alloreactivity. Am J Transplant. 2003;3:646-652
  41. Mohanakumar T, Waldrep JC, Phibbs M, Mendez-Picon G, Kaplan AM, Lee HM. Serological characterization of antibodies eluted from chronically rejected human renal allografts. Transplantation. 1981;32:61-66
  42. Morris PJ, Williams GM, Hume D, Mickey MR, Terasaki PI. Serotyping for homotransplantation: XII. Occurrence of cytotoxicantibodies following kidney transplantation in man. Transplantation. 1968;6:392-399
  43. Lepage V, Gluckman JC, Bedrossian J, Duboust A, Nebout T, Bracq C. Anti-B cell lymphocytotoxic antibodies in kidney transplant recipients. Transplantation. 1978;25:255-258
  44. Mohanakumar T, Rhodes C, Mendez-Picon G, Goldman M, Lee H. Renal allograft rejection associated with presensitization to HLA-DR antigens. Transplantation. 1981;31:93-95
  45. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation. 2003;76:395-400
  46. 47,Leichtman A, Bragg-Gresham J. Final Report for Data Request from the Histocompatibility Committee Meeting of May 2002. UNOS Policy Proposal 7/17/02 2002: Appendix H4
  47. Suciu-Foca N, Rohowsky-Kochan C, Reed E. Idiotypic network regulations of immune responses to HLA. Fed Proc. 1985;44:2483-2487
  48. Claas FHJ, Witvliet M, Duquesnoy RJ, Persijn G, Doxiadis UN. The acceptable mismatch program as a fast tool to transplant highly sensitized patients awaiting a post-mortal kidney: short waiting time and excellent graft outcome. Transplantation. 2004;78:190-193